DUBLIN--(<u>BUSINESS WIRE</u>)--**Research and Markets** (<u>http://www.researchandmarkets.com/research/s32np9/metastatic renal</u>) has announced the addition of the "<u>Metastatic Renal Cell Cancer-Pipeline Insights</u>" report to their offering.

Summary

Metastatic Renal Cell Cancer- Pipeline Insights provides the in-depth analysis of the pipeline assets across the Metastatic Renal Cell Cancer. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Metastatic Renal Cell Cancer Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

Metastatic Renal Cell Cancer- Pipeline Insights Report covers the Metastatic Renal Cell Cancer pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase II, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Metastatic Renal Cell Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.

Scope

- The report provides a Metastatic Renal Cell Cancer Landscape across the globe
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
- Coverage of the Metastatic Renal Cell Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

- Metastatic Renal Cell Cancer Overview
- Metastatic Renal Cell Cancer Pipeline Therapeutics
- Metastatic Renal Cell Cancer Therapeutics under Development by Companies
- Metastatic Renal Cell Cancer Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Metastatic Renal Cell Cancer Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Metastatic Renal Cell Cancer Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Metastatic Renal Cell Cancer Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Metastatic Renal Cell Cancer Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Metastatic Renal Cell Cancer Discontinued Products
- Metastatic Renal Cell Cancer Dormant Products
- Companies Involved in Therapeutics Development for Metastatic Renal Cell Cancer

For more information visit http://www.researchandmarkets.com/research/s32np9/metastatic_re nal

<u>---</u>